TY  - GEN
AU  - Nti,Akosua A
AU  - Serrano,Leona W
AU  - Sandhu,Harpal S
AU  - Uyhazi,Katherine E
AU  - Edelstein,Ilaina D
AU  - Zhou,Elaine J
AU  - Bowman,Scott
AU  - Song,Delu
AU  - Gangadhar,Tara C
AU  - Schuchter,Lynn M
AU  - Mitnick,Sheryl
AU  - Huang,Alexander
AU  - Nichols,Charles W
AU  - Amaravadi,Ravi K
AU  - Kim,Benjamin J
AU  - Aleman,Tomas S
TI  - FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial
SN  - 1539-2864
PY  - 2020///0427
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Enzyme Inhibitors
KW  - Female
KW  - Humans
KW  - Hydroxychloroquine
KW  - Imidazoles
KW  - MAP Kinase Kinase 1
KW  - antagonists & inhibitors
KW  - Macula Lutea
KW  - pathology
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Oximes
KW  - Photoreceptor Cells
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins B-raf
KW  - Pyridones
KW  - Pyrimidinones
KW  - Retinal Diseases
KW  - chemically induced
KW  - Retinal Pigment Epithelium
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1097/IAE.0000000000002027
ER  -